MarketPeel
Insider Trading Intelligence
RS

Ryan Savitz

DNTH
EVP, CFO & CBO · DIANTHUS THERAPEUTICS, INC. /DE/ · CIK 0001992324
FILING MIX · LIFETIME46%/54%
BUYS
12
SELLS
14
TOTAL VALUE
$13.66M
COMPANIES
1
ACTIVE SINCE
Jan 2024
HOLDINGS NOW
8,224
AVG SELL PX
$72.79
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 32 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Ryan Savitz, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+9.09%+1.96%+1.48%+0.48%+1.35%
14d11+18.18%+9.33%+5.39%+3.94%+6.31%
30d11+27.27%+1.64%+8.69%-7.05%-5.88%
60d11+9.09%+6.81%+4.42%-1.49%-1.18%
90d11(1 pending)+0.00%+17.03%+10.20%+6.83%+1.53%
180d11(9 pending)+0.00%+115.39%+4.30%+118.45%+118.45%
1y11(11 pending)
2y11(11 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
DNTH · 8,224 shares · as of Apr 9, 2026
037,50075,000112,500150,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 14 sellsCOVERAGE · 10 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
8,224$89.84$738.8K0Apr 9, 2026Apr 10, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, CFO & CBO
8,22471,776Apr 9, 2026Apr 10, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, CFO & CBO
8,224$17.88$147.0K8,224Apr 9, 2026Apr 10, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
2,366$82.84$196.0K86,501Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
1,485$80.25$119.2K89,667Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
19,469$84.57$1.65M7,232Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, CFO & CBO
74,36710,399Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, CFO & CBO
74,367$8.44$627.7K74,367Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
21,825$78.86$1.72M91,152Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE
EVP, CFO & CBO
40,00080,000Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
EVP, CFO & CBO
40,000$17.88$715.2K114,367Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
7,232$85.54$618.6K0Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
59,800$83.90$5.02M26,701Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
1,390$78.33$108.9K112,977Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
800$81.36$65.1K88,867Mar 31, 2026Apr 1, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
150,000150,000Feb 3, 2026Feb 4, 2026View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
CFO & CBO
20,00084,766Dec 4, 2025Dec 5, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
CFO & CBO
20,000$8.44$168.8K20,000Dec 4, 2025Dec 5, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
20,000$45.18$903.6K0Dec 4, 2025Dec 5, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
60,00060,000Sep 23, 2025Sep 25, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
CFO & CBO
20,000$8.44$168.8K20,000Sep 9, 2025Sep 11, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
SALE10b5-1
10b5-1 plan
20,000$35.00$700.0K0Sep 9, 2025Sep 11, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASE
CFO & CBO
20,000104,766Sep 9, 2025Sep 11, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
150,000150,000Feb 3, 2025Feb 4, 2025View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
100,000100,000May 23, 2024May 28, 2024View →
DNTH
DIANTHUS THERAPEUTICS, INC. /DE/
PURCHASEGRANT
Stock grant
120,000120,000Jan 24, 2024Jan 26, 2024View →
Other insiders · DNTH
Loading peer insiders…
About this filer
CIK 0001992324
ROLE
EVP, CFO & CBO
PRIMARY
DNTH
COMPANIES
1
ACTIVE SINCE
Jan 2024
MARKETPEEL · /INSIDER/0001992324DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback